Company performance
Add to research
Current Price
as of Mar 20, 2025$71.39
P/E Ratio
N/A
Market Cap
$3.81B
Description
Add to research
Arcellx, Inc is a clinical-stage biotechnology company, which provides cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases. The company was founded by David M. Hilbert and Luba Zaritskaya in December 2014 and is headquartered in Gaithersburg, MD.
Metrics
Add to research
Overview
- HQGaithersburg, MD
- SectorHealth Technology
- IndustryBiotechnology
- TickerACLX
- Price$71.39+0.06%
Trading Information
- Market cap$3.81B
- Float73.36%
- Average Daily Volume (1m)697,224
- Average Daily Volume (3m)631,390
- EPS-$2.00
Company
- Revenue$107.94M
- Rev growth (1yr)-2.16%
- Net income-$107.35M
- Gross margin95.19%
- EBITDA margin-122.65%
- EBITDA-$132.38M
- EV$3.57B
- EV/Revenue33.12
- P/EN/A
- P/S35.43
- P/B8.52
- Debt/Equity11.89
Documents
Add to research
SEC Filings
Factset Street Account
Factset